Largest European cohort describing Erivedge® use in real-life setting1

patients with a median age of 75.3 years (61.2–85.7) with laBCC or mBCC* specialised centres in Spain study period Evaluation of OR and toxicity, and analysis of real-life management of patients previously treated with Erivedge®

Efficacy of Erivedge® after a median treatment duration of 32.5 weeks (20.9-56.1)1

Most frequent reasons for interrupting Erivedge®1

Achieving CR (35.9%) Adverse events (27.3%) CR as the main reason for interrupting Erivedge® is in contrast with other studies where the main reason was toxicity1

Safety profile of Erivedge® was consistent with other studies, with predominantly mild to moderate adverse events (grade 1-2)1

Dysgeusia (112 patients; 84.2%) Muscle cramps (92 patients; 69.2%) Alopecia (83 patients; 62.4%) Asthenia (61 patients; 45.9%)

Most common grade 3/4 AEs were muscle cramps (8 patients; 6.0%), asthenia (3 patients; 2.3%) and weightloss (2 patients; 1.5%)

The risk of recurrence after achieving CR with Erivedge® was lower than in previous reports. The RELIVIS study confirms the safety and efficacy of Erivedge® in aBCC1

Click here to request the full publication

Please see full prescribing information for additional important safety information

*115 patients were evaluable for response to subsequent treatments; patients on ErivedgeⓇ in clinical trials were included if 5-year follow-up data were available. AE, adverse event; BCC, basal cell carcinoma; CR, complete response; laBCC, locally advanced BCC; mBCC, multiple BCC;  ORR, objective response rate. 1. Ruiz-Salas V et al. Real-World Experience with Vismodegib on Advanced and Multiple BCCs: Data from the RELIVIS Study. Dermatology. 2023; 239 (5): 685–693.

M-XX-00018376